Cardiff Oncology, Inc. ( (CRDF) ) has released its Q2 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardiff Oncology, Inc., a clinical-stage biotechnology company based in San Diego, California, focuses on developing novel cancer therapies through Polo-like Kinase 1 (PLK1) inhibition, with its lead asset being onvansertib, a PLK1 inhibitor. The company recently released its earnings report for the second quarter of 2025, highlighting a continued focus on advancing its clinical programs despite financial challenges. Key financial metrics from the report indicate a net loss of $13.9 million for the quarter, with research and development expenses increasing to $11.6 million due to ongoing clinical trials and development activities. The company also reported a decrease in cash and cash equivalents to $10.8 million, reflecting its investment in clinical advancements. Looking ahead, Cardiff Oncology remains committed to its strategic focus on developing onvansertib for various cancer indications, with management expressing confidence in its ability to meet funding requirements for the next 12 months.